MZMatthew P. Zimmerman

Matthew P. Zimmerman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Matthew P. Zimmerman has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Harnessing inflammatory monocytes to overcome resistance to anti-PD-1 immunotherapy

    by Matthew P Zimmerman, Amy Y Huang, Emily K Cox, Rose Al Abosy, Wan Lin Chong, Alexander G Bastian, Katherine Vietor, Yacine A Choutri, Jenna L Collier, Vasyl Zhabotynsky, et al.

  • Open Access

    Folate metabolism in tumor-associated macrophages drives immunosuppressive function to promote tumor growth

    by Matthew P Zimmerman, Vasyl Zhabotynsky, Haiyang Wang, Emily K Cox, Wan Lin Chong, Alexander G. Bastian, Andrew S. Kennedy, Brian P. Fay, Amy G. Reynolds, Anna Ebacher, et al.

    Tumor-associated macrophages (TAMs) promote tumor progression, inhibit anti-tumor immunity, and induce resistance to immune checkpoint inhibitors (ICI). Metabolism is a primary determinant of TAM polarization, suggesting therapies that selectively modulate TAM metabolic state may hold therapeutic benefit. Here we demonstrate folate uptake and metabolism sustained by the myeloid-restricted folate receptor beta (FRβ) are critical for TAM immunosuppressive function. Folate was depleted in the microenvironment of human melanomas, suggesting FRβ upregulation by TAMs may be an adaptive response to folate scarcity. FRβ⁺ TAMs exhibited an immunosuppressive phenotype and were associated with immunotherapy resistance in melanoma patients. Genetic ablation of FRβ attenuated tumor growth across multiple cancer models and repolarized macrophages toward pro-inflammatory states, promoting tumor infiltration by activated lymphocytes. Critically, excess folate reversed the phenotypes observed with FRβ loss, suggesting these effects stem from impaired folate uptake by TAMs rather than a folate-independent role for FRβ. Integrated metabolomic, transcriptomic, and functional mechanistic studies demonstrated that folate acquisition via FRβ was required to generate reduced glutathione to limit mitochondrial reactive oxygen species (ROS) production. In the absence of FRβ, mitochondrial oxidative stress promoted canonical NF-kB signaling and macrophage pro-inflammatory polarization. Thus, FRβ couples a nutrient-limited microenvironment to TAM immunosuppressive function and represents a therapeutically tractable metabolic checkpoint for TAMs.

  • Open Access

    Cesium-137 and X-Ray Irradiation Yield Comparable Immune Phenotypes and Activation States in Bone Marrow Chimeric Studies

    by Alexander G. Bastian, Eric W. Livingston, Matthew P. Zimmerman, Amy G. Reynolds, Wan Lin Chong, Emily K. Cox, Haiyang Wang, Hong Yuan, Brian C. Miller

    Bone marrow chimeras are widely used to study immune development and function. As the field moves from cesium-137 ( 137 Cs)-based irradiators to X-ray irradiators for safety reasons, it is essential to determine if there are differences in immune system reconstitution after irradiating mice with one of these two radiation sources. Here, we performed a comprehensive immunological comparison of mice lethally irradiated with 137 Cs or one of two different X-ray platforms and reconstituted with congenic bone marrow. Mice received 12 Gy total body radiation in two 6 Gy sessions followed by intravenous transfer of donor hematopoietic stem cells and were analyzed eight weeks post-transplant. We assessed mouse survival, donor chimerism, immune cell subset distribution, and activation states across multiple organs (bone marrow, spleen, lymph nodes, liver, and lung). All groups exhibited comparable survival and high levels of donor chimerism, with expected organ-specific reconstitution patterns. Immune lineage distributions, CD4/CD8 ratios, and activation states did not differ by irradiation type. Host-derived radioresistant cells were also similar across all irradiation groups and were predominantly composed of T cells skewed toward an activated phenotype. Overall, our data show that X-ray irradiation with proper filters and energy levels (225 KVp and 320 KVp) can yield equivalent immunological outcomes, including immune reconstitution and activation states, as compared to the same radiation dose from 137 Cs-based irradiation in bone marrow chimera models. These results support the continued adoption of X-ray irradiation systems in place of 137 Cs for generating bone marrow chimeras to be used across a wide range of immunologic studies.

  • Open Access

    T cell receptor signaling induces expression of lysine demethylase KDM6B to maintain Treg homeostasis

    by Minghong He, Beisi Xu, Pria G. Bose, Morgan J. McCullough, Rani S. Sellers, Xinying Zong, Wenjie Qi, Brianna L. Banten, Miriya K. Tune, Matthew P. Zimmerman, et al.

    Tregs expressing forkhead box P3 (FOXP3) play crucial roles in maintaining immune tolerance and tissue integrity. EZH2, a histone H3 lysine 27 (H3K27) methyltransferase, is known as a key regulator of Treg identity and suppressive function upon activation. Here, we demonstrate that the H3K27 lysine demethylase KDM6B, which catalyzes the opposing reaction to EZH2, is also required for Treg identity and function after activation. Treg-specific deletion of Kdm6b impaired tissue Treg fate and function. KDM6B was upregulated after T cell antigen receptor signaling in Tregs and contributed to the regulation of Treg-associated gene expression through both direct and indirect mechanisms. A subset of Treg functional genes were direct targets of KDM6B and were co-occupied by FOXP3 at cis -regulatory regions, where KDM6B recruitment limited H3K27me3 accumulation. More broadly, KDM6B-dependent H3K27 demethylation facilitated Treg gene expression programs that supported tissue Treg homeostasis.


  • Open Access

    Harnessing Inflammatory Monocytes to Overcome Resistance to Anti-PD-1 Immunotherapy

    by Matthew P Zimmerman, Amy Y Huang, Emily K Cox, Rose Al Abosy, Wan Lin Chong, Alexander G Bastian, Katherine Vietor, Yacine Choutri, Jenna Collier, Vasyl Zhabotynsky, et al.

    Background: Resistance to immune checkpoint inhibitors represents a major therapeutic challenge, as less than 50% of patients with melanoma achieve long-term response to immune checkpoint inhibitor therapy. One mechanism of acquired resistance involves somatic mutations, such as loss of beta-2 microglobulin ( B2m ), that enable tumor cells to evade T cell-mediated killing. Methods: This study used single-cell RNA-seq, flow cytometry, and ex vivo functional assays to characterize tumor-infiltrating immune cells in antigen presentation-deficient tumors. Tumor-bearing mice were treated with anti-PD-1 or CD40 agonist antibodies and cell depletion or cytokine blocking antibodies to define mechanisms of action. Analysis of published human RNA-seq datasets was performed to dissect the contributions of inflammatory monocytes to patient outcomes. Results: We found an increase in immunosuppressive macrophages in B2m -null tumors. We hypothesized that repolarizing myeloid cells may restore control of tumor growth. Treatment with CD40 agonist antibody, which promotes differentiation of monocytes and macrophages towards a proinflammatory phenotype, reduced tumor growth and improved survival in B2m -null melanoma and colorectal cancer models. Unexpectedly, both CD8 + T cells and NK cells, but not CD4 + T cells, were required for the efficacy of CD40 agonist, even though CD8 + T cells cannot directly recognize antigen presentation-deficient tumor cells. Instead, these lymphocytes control tumor growth via secretion of IFNγ, as depletion of IFNγ inhibited the therapeutic effect of CD40 agonist. IFNγ receptor ( Ifngr1 ) expression was required on host cells, not tumor cells, for CD40 agonist-mediated tumor control. Single-cell analysis identified a distinct population of inflammatory monocytes that were enriched for an IFNγ response signature in CD40 agonist-treated tumors, suggesting that these cells may be important for tumor control. Analysis of human bulk and single-cell RNA-seq datasets demonstrated that an inflammatory monocyte signature derived from our data was associated with improved patient outcomes and response to immune checkpoint inhibitors. Conclusions: These data demonstrate that CD8 + T cells contribute to tumor control even in the absence of direct antigen presentation by tumor cells. More broadly, our work suggests that strategies to activate the effector functions of inflammatory monocytes may limit tumor growth and overcome acquired resistance to immune checkpoint inhibitors.

  • Open Access

    Spon1+ inflammatory monocytes promote collagen remodeling and lung cancer metastasis through lipoprotein receptor 8 signaling

    by Kristina M. Whately, Nisitha Sengottuvel, Lincy Edatt, Sonal Srivastava, Allison T. Woods, Yihsuan S. Tsai, Alessandro Porrello, Matthew P. Zimmerman, Aaron C. Chack, Stuart R. Jefferys, et al.

    Lung cancer is the leading cause of cancer-related deaths in the world, and non–small cell lung cancer (NSCLC) is the most common subset. We previously found that infiltration of tumor inflammatory monocytes (TIMs) into lung squamous carcinoma (LUSC) tumors is associated with increased metastases and poor survival. To further understand how TIMs promote metastases, we compared RNA-Seq profiles of TIMs from several LUSC metastatic models with inflammatory monocytes (IMs) of non–tumor-bearing controls. We identified Spon1 as upregulated in TIMs and found that Spon1 expression in LUSC tumors corresponded with poor survival and enrichment of collagen extracellular matrix signatures. We observed SPON1 + TIMs mediate their effects directly through LRP8 on NSCLC cells, which resulted in TGF-β1 activation and robust production of fibrillar collagens. Using several orthogonal approaches, we demonstrated that SPON1 + TIMs were sufficient to promote NSCLC metastases. Additionally, we found that Spon1 loss in the host, or Lrp8 loss in cancer cells, resulted in a significant decrease of both high-density collagen matrices and metastases. Finally, we confirmed the relevance of the SPON1/LRP8/TGF-β1 axis with collagen production and survival in patients with NSCLC. Taken together, our study describes how SPON1 + TIMs promote collagen remodeling and NSCLC metastases through an LRP8/TGF-β1 signaling axis.